NASDAQ:CMRXChimerix Stock Price, Forecast & News

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CMRX shares have increased by 131.9% and is now trading at $3.34.
View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chimerix.

Chimerix is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Chimerix.

Chimerix will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chimerix Inc (NASDAQ:CMRX) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to analyst estimates of $1.50 million. Chimerix had a negative return on equity of 34.16% and a negative net margin of 923.87%.
View Chimerix's earnings history.

1 Wall Street analysts have issued 1 year price objectives for Chimerix's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Chimerix's stock price to reach $7.00 in the next year. This suggests a possible upside of 109.6% from the stock's current price.
View analysts' price targets for Chimerix.

Media coverage about CMRX stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chimerix earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term.
View the latest news about Chimerix.

Chimerix saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,250,000 shares, an increase of 5.0% from the June 30th total of 1,190,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 1.2 days. Currently, 2.7% of the company's shares are short sold.
View Chimerix's Current Options Chain.

Some companies that are related to Chimerix include Legend Biotech (PLRX), Cara Therapeutics (CARA), Endo International (ENDP), Kura Oncology (KURA), Nkarta (NKTX), Vectura Group (VEGPF), Assembly Biosciences (ASMB), Omeros (OMER), Legend Biotech (AMTI), Tricida (TCDA), Morphic (MORF), ImmunoGen (IMGN), Frequency Therapeutics (FREQ), Akouos (AKUS) and ZIOPHARM Oncology (ZIOP).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Inovio Pharmaceuticals (INO), SLS International (SLS), Wynn Resorts (WYNN), Gilead Sciences (GILD), Opko Health (OPK) and Sorrento Therapeutics (SRNE).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a variety of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.04%), UBS Group AG (0.03%) and Marquette Asset Management LLC (0.03%). Company insiders that own Chimerix stock include Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix.

CMRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Marquette Asset Management LLC.
View insider buying and selling activity for Chimerix.

CMRX stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CMRX stock can currently be purchased for approximately $3.34.

Chimerix has a market capitalization of $206.85 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe.

The official website for Chimerix is www.chimerix.com.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]